Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.55 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | PTAFR | P25105 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3525643 | 0.98 | SMN1; SMN2 (0.55) | SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL | |
| SCHEMBL479199 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL | |
| SCHEMBL671970 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL | |
| SCHEMBL7753858 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL | |
| SCHEMBL672865 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL | |
| SCHEMBL479274 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL | |
| SCHEMBL14967280 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL | |
| SCHEMBL673766 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL | |
| SCHEMBL479150 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL | |
| SCHEMBL672371 | 0.92 | ALDH1A1 (0.60) | SMN1; SMN2NR5A2NR5A1ALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255567-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | Vigil Neuroscience, Inc. (US) | 2023-10-11 | — | — | EP | claimed |
| EP-4192881-A2 | TREATMENT OF DISEASES RELATED TO COLONY-STIMULATING FACTOR 1 RECEPTOR DYSFUNCTION USING TREM2 AGONISTS | Vigil Neuroscience, Inc. (US) | 2023-06-14 | — | — | EP | claimed |
| WO-2022120390-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | VIGIL NEUROSCIENCE, INC. (US) | 2022-06-09 | — | — | WO | claimed |
| EP-3681909-A1 | ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF | Denali Therapeutics Inc. (US) | 2020-07-22 | — | — | EP | claimed |
| WO-2019055841-A1 | ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF | DENALI THERAPEUTICS INC. (US) | 2019-03-21 | — | — | WO | claimed |
| WO-2013032643-A2 | LIPIDS CAPABLE OF CONFORMATIONAL CHANGE AND THEIR USE IN FORMULATIONS TO DELIVER THERAPEUTIC AGENTS TO CELLS | DICERNA PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| EP-4475825-A1 | HYPERACTIVATING LIPID NANOPARTICLES | Corner Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-4347658-A1 | TREM2 AGONIST BIOMARKERS AND METHODS OF USE THEREOF | Vigil Neuoscience, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4322999-A2 | HYPERACTIVATORS OF MAMMALIAN DENDRITIC CELLS | Corner Therapeutics, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2023220747-A1 | NUCLEIC ACIDS ENCODING A CONSTITUTIVELY-ACTIVE CYCLIC GMP-AMP SYNTHASE AND IMMUNOGENIC DELIVERY VEHICLES FOR SAME | CORNER THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4255567-A1 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | Vigil Neuroscience, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023150757-A1 | IMMUNOGENIC MRNA DELIVERY VEHICLES | CORNER THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2023150758-A1 | HYPERACTIVATING LIPID NANOPARTICLES | CORNER THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2009100348-A2 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES ASSOCIATED WITH EYE DISEASE | UAB RESEARCH FOUNDATION (US) | 2009-08-13 | — | — | WO | disclosed |
| EP-1496930-A4 | G-TYPE PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | UNIV CALIFORNIA (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006032905-A1 | TREATMENT OF ATHEROSCLEROSIS | POSTON ROBIN (GB) | 2006-03-30 | — | — | WO | disclosed |
| EP-1626728-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | Vascular Biogenics Ltd. (IL) | 2006-02-22 | — | — | EP | disclosed |
| EP-1496930-A2 | G-TYPE PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | The Regents of The University of California (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004106486-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2004-12-09 | — | — | WO | disclosed |
| WO-2003086326-A2 | G-TYPE PEPTIDES TO AMELIORATE ATHEROSCLEROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-10-23 | — | — | WO | disclosed |